GET DAILY SIGNALSWhy Is Novanta Inc. (NOVT) Stock Down -12.47% Today?
Key Takeaways
- NOVT shares fell 12.47%, or $18.20, to $127.78 in early trading Tuesday, down from Monday's close of $145.98 — the stock's steepest single-session drop in recent months.
- The primary catalyst was a mixed third-quarter report: revenue and adjusted earnings beat consensus, but fourth-quarter adjusted EPS guidance of $0.91 to $0.96 came in well below the $1.02 analysts expected.
- Secondary drivers compounded the selling: GAAP net income collapsed to $2.0 million from $10.7 million, operating margin fell to 4.6% from 11.5%, and management flagged a production slowdown at its Stockport, U.K. facility.
- Full-year adjusted EPS guidance was trimmed to $3.66 to $3.71 from a prior $3.68 to $3.74 range, hardening the margin-compression narrative.
- The move was company-specific: broad indices, health care and robotics exchange-traded funds were only modestly lower.
- News Significance Score: 62/100 — a material guidance and margin shortfall amplified by a selloff roughly five times the stock's normal daily swing.
- Traders are now watching whether the $120 to $128 area holds and whether sell-side models get cut this week.
- Investors can dig deeper into Price Targets, Earnings and Forecast pages for detailed historical and forward-looking data.
- Explore Trending AI Robots to see which automated strategies are performing best in the current market.
Opening Summary: Novanta Shares Slide After Soft Fourth-Quarter Outlook
Novanta Inc. (NOVT) is a Bedford, Massachusetts-based supplier of precision motion, photonics and medical technology subsystems used by original equipment manufacturers in surgical robotics, life sciences, semiconductor and advanced industrial markets. The stock closed Monday at $145.98 and was trading at $127.78 shortly after Tuesday's opening bell, a decline of $18.20, or 12.47%. The direction is clearly negative, and the cause is verified: Novanta reported third-quarter 2026 results after Monday's close and guided fourth-quarter adjusted earnings below consensus while acknowledging margin pressure that management expects to persist through year-end. A rally of more than 8% in Monday's regular session ahead of the release added a layer of profit-taking to the reaction.
Earnings Beat Overshadowed by Guidance Shortfall
The quarter itself was solid. Revenue rose 23.1% year over year to $305.0 million, ahead of the roughly $301 million consensus, with organic growth near 10% — the company's strongest in more than three years. Adjusted earnings per share of $1.05 beat the $0.97 consensus by 8.6%, and adjusted EBITDA climbed 38% to $80.3 million, a 26.0% margin and an all-time high. Bookings rose 29%, producing a book-to-bill of 1.08 and backlog of $543 million.
The forward view is where the story broke down. Novanta guided fourth-quarter revenue to $306 million to $312 million, essentially in line with consensus, but projected adjusted EPS of $0.91 to $0.96 against an expected $1.02 — a shortfall of roughly 8% at the midpoint. Full-year adjusted EPS guidance was reduced to $3.66 to $3.71 from $3.68 to $3.74. For a stock trading near 86 times trailing earnings, even a modest trim to the profit path was enough to force a de-rating.
Margin Pressure and a Steep GAAP Profit Decline
Beneath the adjusted figures, generally accepted accounting principles results deteriorated sharply. GAAP net income fell to $2.0 million, or $0.05 per diluted share, from $10.7 million, or $0.30, a year earlier. Operating income dropped to $13.9 million from $21.8 million and operating margin compressed to 4.6% from 11.5%. Medical Solutions gross margin slipped to 39.9% from 43.0%.
Management attributed much of the pressure to a temporary production slowdown at its Stockport, U.K. factory for the remainder of the year, with normal output not expected to resume until the first quarter of 2027. It also noted that the first full quarter of the Riverpoint Medical acquisition — the largest in company history — took net debt to $689 million from a net cash position at the end of 2025. Investors have so far tolerated that leverage while margins were expanding; Tuesday's print challenged that assumption.
Market Context and Trading Activity
Turnover was heavy relative to the stock's roughly 400,000-share average daily volume, with more than 32,000 shares changing hands in the first five minutes alone. The shares gapped down from Monday's $145.98 close, opened near $134 and touched $120.24 before stabilizing in the high-$120s, breaking below the October closing low of $128.79 and leaving the stock roughly 28% below its 52-week high of $176.38.
The weakness was idiosyncratic rather than systemic. Broad benchmarks, health care sector funds and robotics-focused ETFs were all down less than 1% at the same hour. That divergence confirms the selloff is a company-specific repricing of earnings power and margins, not a sector rotation. The failure to hold the $145 to $147 zone — where the 50-day and 200-day moving averages had converged — is technically significant.
News Significance Score
The score runs from 0, meaning no meaningful news and a routine price move, to 100, meaning transformative news and an extreme, rare move. Novanta's verified news is material but not transformative: a modest revenue and adjusted profit beat was outweighed by a fourth-quarter earnings guidance miss, a trimmed full-year profit range, and a GAAP operating margin cut nearly in half. The price reaction was exceptional — 12.47% is roughly five times the stock's typical daily move of about 2.5%, and no session in the past 60 trading days produced a larger absolute swing.
Strong fundamental news combined with a rare move produces 62 out of 100. Neither component alone explains the session; together they capture why this earnings-driven move was so forceful.
What Comes Next for NOVT
Attention turns to the fourth quarter, when Novanta must show that the Stockport disruption is genuinely temporary and that gross margin can recover toward the high-40s as guided. Management has tied roughly 100 basis points of 2027 margin expansion to that restart, so any delay into the second quarter would be poorly received.
Sell-side analysts are likely to revise fourth-quarter and full-year models this week, with the debate centered on whether the earnings shortfall is a one-off operational issue or a sign of structural cost pressure from tariffs, factory relocations and the Riverpoint integration. Watch the upcoming quarterly report for bookings and backlog trends — a book-to-bill above 1.0 would support the demand thesis — along with any updates on factory consolidation, net debt reduction and the industrial and semiconductor end markets that drive the automation segment. Risks remain two-sided: a smooth production restart would argue for recovery, while another margin miss against a premium multiple would invite further pressure.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of automated trading strategies, drawn from hundreds of AI bots covering thousands of tickers. Only the strongest performers under current market conditions make the featured list, and the bots differ widely by strategy, timeframe, performance metrics and the symbols they trade — from momentum and swing systems to intraday models. For readers tracking volatility in names like NOVT, the page is a practical way to compare live strategy performance and find approaches suited to the present environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NOVT in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026
The 10-day moving average for NOVT crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 64 cases where NOVT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on NOVT as a result. In 61 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
NOVT moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where NOVT advanced for three days, in 195 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
NOVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for NOVT turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 37 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
The 50-day moving average for NOVT moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NOVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. NOVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.162) is normal, around the industry mean (1.448). P/E Ratio (85.000) is within average values for comparable stocks, (5.350). NOVT's Projected Growth (PEG Ratio) (23.270) is slightly higher than the industry average of (5.470). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (5.043) is also within normal values, averaging (32.028).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of manufactures and sells precision photonic and motion control components
Industry ElectronicEquipmentInstruments
Advertisement